Tesi sul tema "Cervical Cancer"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Vedi i top-50 saggi (tesi di laurea o di dottorato) per l'attività di ricerca sul tema "Cervical Cancer".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Vedi le tesi di molte aree scientifiche e compila una bibliografia corretta.
Ibrahim, Emad Moussa. "CD44 in cervical cancer". Thesis, University of Sheffield, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.269370.
Testo completoThornton, Julia Susan. "Screening for cervical cancer". Thesis, City University London, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.241442.
Testo completoNevin, James. "Pregnancy-associated cervical cancer". Thesis, University of Cape Town, 1991. http://hdl.handle.net/11427/26272.
Testo completoRatima, Keri, e n/a. "Cervical cancer in Maori women". University of Otago. Dunedin School of Medicine, 1994. http://adt.otago.ac.nz./public/adt-NZDU20070601.112003.
Testo completoGovorukhina, Natalia I. "Biomarker discovery for cervical cancer". [S.l. : Groningen : s.n. ; University Library of Groningen] [Host], 2007. http://irs.ub.rug.nl/ppn/305362089.
Testo completoRoeder, Geraldine Elizabeth. "Gene therapy for cervical cancer". Thesis, University of Bristol, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.268704.
Testo completoLi, Xing. "Novel brachytherapy techniques for cervical cancer and prostate cancer". Diss., University of Iowa, 2015. https://ir.uiowa.edu/etd/1682.
Testo completoGunnell, Anthony S. "Risk factors for cervical cancer development /". Stockholm, 2007. http://diss.kib.ki.se/2007/978-91-7357-437-2/.
Testo completo張德凱 e Dekai Zhang. "Telomerase activation in human cervical cancer". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 1998. http://hub.hku.hk/bib/B31238038.
Testo completoNg, Grace. "Genomic investigations of cervical cancer progression". Thesis, University of Cambridge, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.613036.
Testo completoZhang, Dekai. "Telomerase activation in human cervical cancer /". Hong Kong : University of Hong Kong, 1998. http://sunzi.lib.hku.hk/hkuto/record.jsp?B20666755.
Testo completoFiander, Alison Nina. "Immunological responses in cervical neoplasia : immunological status of patients with cervical carcinoma and HPV-specific cytotoxic lymphocyte responses in women with cervical neoplasia". Thesis, University of Southampton, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.241944.
Testo completo吳曉靑 e Xiaoqing Wu. "Post-radiotherapy cervical metastasis in nasopharyngeal carcinoma". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 1999. http://hub.hku.hk/bib/B31222018.
Testo completoTidy, John Anthony. "Human papillomaviruses and cervical neoplasia". Thesis, Imperial College London, 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.267104.
Testo completoStrander, Björn. "Cervical cancer prevention : studies on possible improvements /". Göteborg : Dept. of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, Göteborg University, 2008. http://hdl.handle.net/2077/8513.
Testo completoCorden, Sally Anne. "HPV-18 DNA integration in cervical cancer". Thesis, University of Warwick, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.267050.
Testo completoYang, Wenjun. "Rotating-shield brachytherapy (RSBT) for cervical cancer". Thesis, University of Iowa, 2012. https://ir.uiowa.edu/etd/3410.
Testo completoBolger, Brendan Stephen. "Cell cycle kinetics in cervical tumours". Thesis, Imperial College London, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.294984.
Testo completoIbekwe, Chidiebere Maquincy. "Factors influencing cervical cancer screening uptake among women attending Mahalapye district hospital in Botswana-use of the health belief model". Thesis, University of Limpopo ( Medunsa Campus ), 2009. http://hdl.handle.net/10386/227.
Testo completoCervical cancer is the second highest form of cancer among women in Botswana, with breast cancer being the commonest (Ferlay et al, 2002), and is currently the highest cause of cancer deaths in Botswana (Ferlay et al, 2002). Cervical cancer screening using Pap smear provides an appropriate way for early detection and prevention of cervical cancer if appropriately implemented. Cervical cancer screening was introduced in Botswana in 2003 free of charge to all women of age greater than 18 years attending government hospitals. Despite this step by the government to decrease the mortality and morbidity rates resulting from cervical cancer, the uptake of cervical cancer has remained low among women in Botswana (Botswana central statistic report, 2009). Aim of the study; The study was aimed at identifying and describing factors influencing cervical cancer screening uptake among women greater than 18 years attending Mahalapye District Hospital in Botswana using the Health Belief Model. Methodology; This study was a cross sectional survey in which a questionnaire was used to interview 300 participants in order to assess their perceived susceptibility to cervical cancer, their perceived severity of cervical cancer, their perceived benefits of doing cervical cancer screening and their perceived barriers of seeking cervical cancer screening. Descriptive statistics was used to identify and describe factors influencing cervical cancer screening uptake among women attending Mahalapye District Hospital, Botswana using the Health Belief Model construct. Each question in the questionnaire was scored using a 5-point Likert scale ranged from strongly agree (5) to disagree (1). Negatively worded questions had their scales reversed and scores for each construct of the Health Belief Model was added to get an average. Analysis compared women who had ever had „cervical cancer screening‟ with women who had never had „cervical cancer screening‟. Chi-square statistic was used to test for association of selected variables and binary logistic regression was used to measure the associations for the aggregate score of health belief model constructs. Results; Cervical cancer screening rates was 39%. Participants were aware of the perceived severity of cervical cancer (average response 2.58-3.60), perceived benefits of cervical cancer 6 screening (average response 3.10-4.33) and perceived barriers to seeking cervical cancer screening (average response 2.0-3.44) but these were not significantly associated with screening. The highest predictor of cervical cancer screening was perceived susceptibility and those with high perceived susceptibility were 3.2 times more likely to do cervical cancer screening than those with low perceived susceptibility. Main socio-demographic characteristics significantly associated with perceived susceptibility were employment, monthly income and residential area while perceived severity was significantly associated with monthly income and residential area. Conclusions; Perceived susceptibility to cervical cancer was significantly associated with cervical cancer screening. Educational programs geared towards increasing perceived susceptibility to cervical cancer can significantly improve the uptake of cervical cancer screening in Botswana as well as address issues of barriers and misconceptions associated with low uptake of cervical cancer screening.
Evans, Mark Francis. "Molecular genetic analysis of cervical dysplasia". Thesis, University of Hertfordshire, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.338560.
Testo completoFrank, Luiza Abrahão. "Desenvolvimento de formulações nanotecnológicas contendo imiquimode para o tratamento do câncer cervical". reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2017. http://hdl.handle.net/10183/179271.
Testo completoThis thesis deals with the need of new treatments for cervical cancer in order to increase the adherence of patients to the treatment as well as to improve their quality of life. In this sense, nanotechnological formulations were developed to carry imiquimod to a specific site – the vaginal mucosa – expecting to obtain better performance than the commercial drug in the cervical cancer treatment. Three nanostructures with different morphologies were proposed to potentilize the drug effect on cervical cancer cells (SiHa). The developed formulations are: nanoemulsions (NEimiq), polymeric nanocapsules (NCimiq) and polymeric nanocapsules coated with chitosan (NCimiq-chit). It was observed that polymeric nanocapsules produced with poly(ε-caprolactone) presented a stronger effect against SiHa cells. Therefore, formulations NCimiq and NCimiq-chit were incorporated into hydrogels of chitosan and hydroxyethylcellulose to enable a better future application on patients. The studies of this thesis involving porcine vaginal mucosa demonstrated that both formulations are mucoadhesive and that they provided a good drug permeation. However, the formulation produced with chitosan hydrogel (NCimiq) showed a better performance. This formulation was therefore chosen to follow the next steps of this work, conducted in SiHa cell culture to elucidate its action mechanism. This study demonstrated that there is an occurrence of combined processes of decreasing cell viability in a time-dependent type. The study also showed that mechanisms such as apoptosis, autophagy and cell cycle arrest are simultaneously present. The formulation NCimiq presented a significantly percentage of cellular death, even when low concentrations of the drug were used. Consequently, the findings of this thesis indicate that nanostructures effectively modulate the interaction of the drug with the cancer cells.
Waller, Josephine. "The viral aetiology of cervical cancer : psychosocial issues". Thesis, University College London (University of London), 2005. http://discovery.ucl.ac.uk/1446882/.
Testo completoBrestovac, Brian. "Human papillomavirus and cervical cancer in Western Australia". University of Western Australia. School of Biomedical and Chemical Sciences, 2005. http://theses.library.uwa.edu.au/adt-WU2006.0037.
Testo completoKulaga, Sophie. "Determinants of incident precursor lesions of cervical cancer". Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape11/PQDD_0006/MQ44199.pdf.
Testo completoBremer, Gerardus Leonardus. "Tumour stroma in cervical cancer, novel prognostic parameters". Maastricht : Maastricht : Universitaire Pers Maastricht ; University Library, Maastricht University [Host], 1995. http://arno.unimaas.nl/show.cgi?fid=8350.
Testo completoSiliņš, Ilvars. "Molecular epidemiology of human papillomavirus and cervical cancer /". Stockholm : [Karolinska institutets bibl.], 2001. http://diss.kib.ki.se/2001/91-7349-091-1/.
Testo completoGalbraith, Kevin. "Cervical cancer screening in Hong Kong : addressing inequity /". Thesis, Click to view the E-thesis via HKUTO, 2005. http://sunzi.lib.hku.hk/hkuto/record/b39724104.
Testo completoVan, Trappen Philippe Octaaf. "Lymphangiogenesis and lymph node microdissemination in cervical cancer". Thesis, Queen Mary, University of London, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.408026.
Testo completoJha, Prabhat K. S. "Epidemiological studies of infectious agents in cervical cancer". Thesis, University of Oxford, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.316863.
Testo completoShen, Meng-Ru. "Volume-regulatory mechanisms in human cervical cancer cells". Thesis, University of Oxford, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.393616.
Testo completoWong, Tsz-lo, e 黃子璐. "Cellular role of miR-143 in cervical cancer". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B48274045.
Testo completopublished_or_final_version
Pathology
Master
Master of Medical Sciences
Kirby, Alison Jill. "Statistical modelling for the precursors of cervical cancer". Thesis, University of Cambridge, 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.303111.
Testo completoTieche, Sarah Marie. "Somatic Acquisition of TGFBR1*6A in Cervical Cancer". The Ohio State University, 2008. http://rave.ohiolink.edu/etdc/view?acc_num=osu1228313120.
Testo completoShields, Tammy S. "Endogenous hormones and the risk of cervical cancer /". Thesis, Connect to this title online; UW restricted, 2002. http://hdl.handle.net/1773/10909.
Testo completoNji, Anna Nkapsah. "Perceptions of Cameroonian Women Regarding Cervical Cancer Prevention". ScholarWorks, 2016. https://scholarworks.waldenu.edu/dissertations/2223.
Testo completoWood, Brianne. "Woman-centered Cervical Screening: Identifying Women's Preferences and Factors Related to Their Preferences in Cervical Cancer Screening". Thesis, Université d'Ottawa / University of Ottawa, 2019. http://hdl.handle.net/10393/38748.
Testo completoWu, Xiaoqing. "Post-radiotherapy cervical metastasis in nasopharyngeal carcinoma /". Hong Kong : University of Hong Kong, 1999. http://sunzi.lib.hku.hk/hkuto/record.jsp?B20843252.
Testo completoFlannelly, Grainne. "A prospective study of women with mild and moderate dyskaryosis and other studies". Thesis, University of Aberdeen, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.263652.
Testo completoPalmer, Ann. "Population coverage in cervical cytology programmes". Thesis, University of Edinburgh, 1988. http://hdl.handle.net/1842/19212.
Testo completo韋霖 e William I. Wei. "Surgery for post-radiotherapy cervical metastasis in nasopharyngeal carcinoma". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 1991. http://hub.hku.hk/bib/B31979543.
Testo completo黃鳳如 e Fung-yu Huang. "Molecular and cytogenetic analysis of cervical and vulvar cancer". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2002. http://hub.hku.hk/bib/B26662188.
Testo completoDi, Jiangli. "A Comprehensive Assessment of the Quality of the Cervical Cancer Screening Program in Rural China". Thesis, Griffith University, 2016. http://hdl.handle.net/10072/367999.
Testo completoThesis (PhD Doctorate)
Doctor of Philosophy (PhD)
Griffith School of Environment
Science, Environment, Engineering and Technology
Full Text
Wolstenholme, Jane. "Counting the costs of cancer care : breast, cervical and lung cancer in Trent". Thesis, University of Nottingham, 2001. http://eprints.nottingham.ac.uk/12097/.
Testo completoTseng, Roger Sean. "High-risk HPV: From Infection to Cervical Cancer Progression". Thesis, The University of Arizona, 2015. http://hdl.handle.net/10150/604865.
Testo completoCullimore, John Edward. "Prospects for primary and secondary prevention of cervical adenocarcinoma". Thesis, University College London (University of London), 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.261819.
Testo completoIvansson, Emma. "Contribution of Immunogenetic Factors in Susceptibility to Cervical Cancer". Doctoral thesis, Uppsala universitet, Institutionen för genetik och patologi, 2009. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-9552.
Testo completoSpence, Andrea Rose. "Process of care failures in women with cervical cancer". Thesis, McGill University, 2012. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=107607.
Testo completoDurant l'année 2010, environ 1300 cas incidents de cancer du col de l'utérus sont estimés avoir été diagnostiqués au Canada, ce qui en fait la 3e cause la plus importante de cancer chez les femmes canadiennes âgées entre 20 et 49 ans. Objectifs: Évaluer la qualité des soins de santé que les femmes atteintes de cancer invasif du col de l'utérus ont reçus dans les 5 années qui ont précédé leur diagnostic. Le but est de déterminer les faiblesses au niveau du dépistage avec le test Pap, des diagnostics et des traitements des lésions pré-invasives chez les participantes de l'étude. Méthodes: Une étude cas-témoins a été réalisée. Les participantes de l'étude étaient résidantes depuis longtemps à Montréal ou Laval et avaient reçu un diagnostic de cancer primaire du col de l'utérus (confirmé par histologie) entre le 1er janvier 1998 et le 31 décembre 2004. L'identification des cas a été faite par le registre des tumeurs du Québec et par les départements d'archives médicales d'hôpitaux. L'historique du dépistage Pap, du diagnostic et des traitements des lésions pré-invasives a été obtenu à partir de la revue des dossiers médicaux, des laboratoires de cytologie des hôpitaux, des entrevues des participantes (ou proxy) et des questionnaires relatifs aux médecins. La durée d'observation considérée à été principalement la période de 0-5 ans précédant le diagnostic, par contre, tout l'historique de dépistage à vie de la participante a aussi été considéré. Le processus des soins a été évalué selon des critères médicaux définis à partir des guides de pratiques cliniques et de consensus des co-chercheurs cliniciens. Les répondantes à l'Enquête sur la santé de la communauté canadienne (cycle 2.1) et un échantillon apparié de sujets sans cancer du col de l'utérus obtenu de la Régie de l'assurance maladie du Québec ont été utilisées comme groupe de comparaison pour plusieurs analyses. Des statistiques descriptives et des techniques de modélisation de régression ont été effectuées pour évaluer les mesures d'association. Résultats: Un total de 568 femmes ont reçu un diagnostic de cancer du col de l'utérus et respectaient les critères d'inclusion. Les immigrantes (OR 1.40, IC 95% : 1.08-1.82), les femmes vivant en union de fait (OR 1.62, IC 95% : 1.12-2.33) et les femmes ne parlant ni français ni anglais (OR 4.53, IC 95% : 2.26-9.07) avaient un plus grand risque de cancer du col de l'utérus. La majorité des cas de cancer du col de l'utérus (celles dont l'historique de dépistage pouvaient être classifié) avait eu au moins un test de dépistage au cours de leur vie (90.4%, IC 95% : 87.5-93.3) et 9.6% (IC 95% : 6.7-12.5) n'avaient jamais eu de test de dépistage. De ces femmes qui ont eu un test de dépistage au cours de leur vie, 43,1% (IC 95% : 38.0-48.2%) n'ont pas eu de dépistage au cours des 5 années précédant leur diagnostic. Le plus haut risque a été trouvé chez des femmes ayant eu un test de dépistage 5 ans et plus avant leur diagnostic (OR 14.4, IC 95% : 9.94-20.91). Spécifiquement, 12.5% (IC 95% : 8.7-16.3) des participantes avec un test Pap anormal et 19.4% (IC 95% : 13.9-24.9) des participantes diagnostiquées avec des lésions cervicales, n'avaient pas eu de suivi approprié selon les critères médicaux définis. De même, 36.7% (IC 95% : 31.2-42.3) des participantes avec un test Pap anormal et 52.5% (IC 95% : 45.5-59.4) des participantes avec des lésions cervicales n'ont pas été gérées de façon appropriée. Conclusion: La plupart des femmes qui ont reçu un diagnostic de cancer du col utérin ont eu au moins un test de dépistage au cours de leur vie. Cependant, plusieurs femmes avec un cancer du col de l'utérus n'ont pas eu de test de dépistage dans les 5 ans précédant leur diagnostic. Si un test Pap anormal survenait ou si des lésions précancéreuses étaient diagnostiquées, le processus des soins a été reconnu comme acceptable dans la plupart des cas; cependant, des délais dans la mise en œuvre de ces processus ont été fréquents.
Baussano, Iacopo. "HPV-16 Infection and Cervical Cancer : A dynamic model". Thesis, Imperial College London, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.526378.
Testo completoCheung, Nga-yin Annie, e 張雅賢. "Cervical cancer screening: evolution from Paptest to molecular markers". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B46540465.
Testo completoLorenzato, Felipe Rinald Barbosa. "Cervical cancer prevention and the role of human papillomavirus". Thesis, University College London (University of London), 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.268718.
Testo completo